Phost'in Therapeutics

Phost'in Therapeutics is a clinical-stage biotech developing first-in-class oral inhibitors of aberrant N-glycosylation, a novel immune checkpoint. Its lead asset, PhOx430, is in an adaptive Phase I/II trial (PhAST) for advanced solid tumors and has shown strong preclinical efficacy with a favorable safety profile. The company has secured significant non-dilutive funding from French government initiatives and a strategic option/license agreement with Taiho Pharmaceutical, validating its platform's potential in oncology and chronic fibrosis. Backed by strong academic IP and a lean management team, Phost'in is positioned at the intersection of glycoscience and immuno-oncology.

Discovery platform for first-in-class small molecule glycocalyx modifiers, specifically targeting aberrant N-glycosylation via inhibition of enzymes like GnT-V. The platform uses a proprietary chemical scaffold ('Phostines') to create oral inhibitors that unmask tumors to the immune system and reduce invasiveness.

Phost'in is a pioneer in clinical-stage Glyco-Immuno-Oncology, facing limited direct competition. The competitive landscape consists of earlier-stage academic and biotech efforts targeting other glycosylation enzymes or glycan-binding proteins (lectins). In fibrosis, competition is from established and pipeline anti-fibrotics with different mechanisms. The company's lead and oral administration provide a distinct profile.